CSL (OTCMKTS:CSLLY) Shares Up 23.5% – Time to Buy?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s stock price rose 23.5% during trading on Wednesday . The stock traded as high as $29.71 and last traded at $29.59. 38,875 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 411,140 shares. The stock had previously closed at $23.95.

Analyst Ratings Changes

Several brokerages have recently weighed in on CSLLY. Canaccord Genuity Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Jefferies Financial Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Citigroup lowered CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a report on Friday, August 7th. Five investment analysts have rated the stock with a Hold rating, According to MarketBeat, CSL presently has a consensus rating of “Hold”.

CSL Price Performance

The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57. The company has a 50 day moving average price of $21.34 and a 200 day moving average price of $27.26.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.